The role of cytokines in the pathogenesis of systemic lupus erythematosus - From bench to bedside

Nephrology

Volumn 18, Issue 4, 2013, Pages 243-255

  Yap, Desmond Yat Hin ^a   Lai, Kar Neng ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

BLys; IFN; IL 17; IL 18; IL 6; systemic lupus erythematosus; TNF

Indexed keywords

ATACICEPT; B CELL MATURATION ANTIGEN; BELIMUMAB; C REACTIVE PROTEIN; CD5 ANTIGEN; CYTOKINE; GELATINASE B; GLYCOPROTEIN GP 130; INFLIXIMAB; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIFALIMUMAB; TOCILIZUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

AMYLOIDOSIS; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELLS; CYTOKINE RELEASE; DENDRITIC CELL; DIMERIZATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENTERITIS; FIBROBLAST; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC POLYMORPHISM; GLOMERULONEPHRITIS; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN PRODUCTION; KILLER CELL; LIVER CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOBLASTOID CELL; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVIEW; SJOEGREN SYNDROME; SPLEEN CELL; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; THROMBOCYTOPOIESIS; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; BIOLOGICAL AGENTS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84875751473     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12047     Document Type: Review

References (147)

1. Schimpl A, Wecker E,. Replacement of T-cell function by a T-cell product. Nat. New Biol. 1972; 237: 15-17.
2. Tackey E, Lipsky PE, Illei GG,. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-343.
3. Rose-John S,. IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 2012; 8: 1237-1247.
4. Rose-John S, Heinrich PC,. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem. J. 1994; 300 (Pt 2): 281-290.
5. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573-581.
6. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 1993; 23: 1078-1082.
7. Tang B, Matsuda T, Akira S, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int. Immunol. 1991; 3: 273-278.
8. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ,. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am. J. Pathol. 1994; 144: 927-937.
9. Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J. Rheumatol. 2010; 37: 60-70.
10. Finck BK, Chan B, Wofsy D,. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 1994; 94: 585-591.
11. Mihara M, Takagi N, Takeda Y, Ohsugi Y,. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol. 1998; 112: 397-402.
12. Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM,. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 2009; 113: 4534-4540.
13. Tagoh H, Kishi H, Muraguchi A,. Molecular cloning and characterization of a novel stromal cell-derived cDNA encoding a protein that facilitates gene activation of recombination activating gene (RAG)-1 in human lymphoid progenitors. Biochem. Biophys. Res. Commun. 1996; 221: 744-749.
14. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I,. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2000; 18: 565-570.
15. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR,. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 1991; 147: 117-123.
16. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH,. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum. 1991; 34: 276-286.
17. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: Analysis of IL-6 production and IL-6R expression. Clin. Exp. Immunol. 1992; 88: 75-83.
18. Kitani A, Hara M, Hirose T, et al. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 1989; 77: 31-36.
19. Garaud S, Le Dantec C, Jousse-Joulin S, et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 2009; 182: 5623-5632.
20. Huang CM, Huo AP, Tsai CH, Chen CL, Tsai FJ,. Lack of association of interleukin-6 and interleukin-8 gene polymorphisms in Chinese patients with systemic lupus erythematosus. J. Clin. Lab. Anal. 2006; 20: 255-259.
21. Santos MJ, Fernandes D, Capela S, da Silva JC, Fonseca JE,. Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin. Rheumatol. 2011; 30: 409-413.
22. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG,. The association between interleukin-6 polymorphisms and systemic lupus erythematosus: A meta-analysis. Lupus 2012; 21: 60-67.
23. Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin. Nephrol. 1993; 40: 16-21.
24. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY,. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000; 85: 207-214.
25. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E,. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998; 7: 154-158.
26. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H,. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol. 2009; 28: 1319-1323.
27. Eilertsen GO, Nikolaisen C, Becker-Merok A, Nossent JC,. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus 2011; 20: 607-613.
28. Lech M, Rommele C, Anders HJ,. Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. Nephrol. Dial. Transplant. 2012 [Epub ahead of print].
29. Esposito P, Balletta MM, Procino A, Postiglione L, Memoli B,. Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus 2009; 18: 1329-1330.
30. De La Torre M, Urra JM, Blanco J,. Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? Lupus 2009; 18: 216-222.
31. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62: 542-552.
32. Makol A, Gibson LE, Michet CJ,. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J. Clin. Rheumatol. 2012; 18: 92-95.
33. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
34. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63: 3918-3930.
35. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
36. Moore PA, Belvedere O, Orr A, et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
37. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.
38. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111: 1004-1012.
39. Xu S, Lam KP,. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 2001; 21: 4067-4074.
40. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 2001; 11: 1547-1552.
41. Hikida M, Johmura S, Hashimoto A, Takezaki M, Kurosaki T,. Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development. J. Exp. Med. 2003; 198: 581-589.
42. Hatada EN, Do RK, Orlofsky A, et al. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J. Immunol. 2003; 171: 761-768.
43. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999; 190: 1697-1710.
44. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
45. Hondowicz BD, Alexander ST, Quinn WJ, 3rd, et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int. Immunol. 2007; 19: 465-475.
46. Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. 2000; 192: 129-135.
47. Groom J, Mackay F,. B cells flying solo. Immunol. Cell Biol. 2008; 86: 40-46.
48. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001; 44: 1313-1319.
49. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann. Rheum. Dis. 2012; 71: 1833-1838.
50. Dooley M, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22: 63-72.
51. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res. Ther. 2012; 14: R33.
52. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P,. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993; 150: 5445-5456.
53. Sutton CE, Mielke LA, Mills KH,. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 2012; 42: 2221-2231.
54. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 2011; 187: 490-500.
55. Weaver CT, Hatton RD, Mangan PR, Harrington LE,. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007; 25: 821-852.
56. Agarwal S, Misra R, Aggarwal A,. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 2008; 35: 515-519.
57. Albanesi C, Cavani A, Girolomoni G,. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha. J. Immunol. 1999; 162: 494-502.
58. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
59. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
60. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005; 201: 233-240.
61. Aggarwal S, Ghilardi N, Xie MH, de, Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003; 278: 1910-1914.
62. Nalbandian A, Crispin JC, Tsokos GC,. Interleukin-17 and systemic lupus erythematosus: Current concepts. Clin. Exp. Immunol. 2009; 157: 209-215.
63. Edgerton C, Crispin JC, Moratz CM, et al. IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clin. Immunol. 2009; 130: 313-321.
64. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 2008; 9: 166-175.
65. Kang HK, Liu M, Datta SK,. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J. Immunol. 2007; 178: 7849-7858.
66. Zhang Z, Kyttaris VC, Tsokos GC,. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009; 183: 3160-3169.
67. Pisitkun P, Ha HL, Wang H, et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012; 37: 1104-1115.
68. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC,. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 2010; 184: 4605-4609.
69. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW,. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 2008; 127: 385-393.
70. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008; 181: 8761-8766.
71. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 2009; 10: 778-785.
72. Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009; 60: 1472-1483.
73. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC,. T cells as therapeutic targets in SLE. Nature reviews. Rheumatology 2010; 6: 317-325.
74. Takeuchi O, Akira S,. Innate immunity to virus infection. Immunol. Rev. 2009; 227: 75-86.
75. Beutler B,. The Toll-like receptors: Analysis by forward genetic methods. Immunogenetics 2005; 57: 385-392.
76. Fitzgerald-Bocarsly P, Dai J, Singh S,. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine & Growth Factor Reviews 2008; 19: 3-19.
77. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L,. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004; 50: 1861-1872.
78. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. U.S.A. 2003; 100: 2610-2615.
79. Strandberg L, Ambrosi A, Espinosa A, et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J. Clin. Immunol. 2008; 28: 220-231.
80. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN,. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 2007; 13: 543-551.
81. Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: Enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 2006; 176: 2074-2078.
82. Uccellini MB, Busconi L, Green NM, et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J. Immunol. 2008; 181: 5875-5884.
83. Braun D, Geraldes P, Demengeot J,. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 2003; 20: 15-25.
84. Jorgensen TN, Thurman J, Izui S, et al. Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice. Genes Immun. 2006; 7: 555-567.
85. Triantafyllopoulou A, Franzke CW, Seshan SV, et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc. Natl Acad. Sci. U.S.A. 2010; 107: 3012-3017.
86. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S,. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J. Immunol. 2005; 174: 2499-2506.
87. Fairhurst AM, Mathian A, Connolly JE, et al. Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur. J. Immunol. 2008; 38: 1948-1960.
88. Ramanujam M, Kahn P, Huang W, et al. Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum. 2009; 60: 1096-1101.
89. Liu Z, Bethunaickan R, Huang W, et al. Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 2011; 63: 219-229.
90. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003; 197: 777-788.
91. Agrawal H, Jacob N, Carreras E, et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J. Immunol. 2009; 183: 6021-6029.
92. Nacionales DC, Kelly-Scumpia KM, Lee PY, et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007; 56: 3770-3783.
93. Lee PY, Kumagai Y, Li Y, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 2008; 205: 2995-3006.
94. Fairhurst AM, Hwang SH, Wang A, et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur. J. Immunol. 2008; 38: 1971-1978.
95. Savarese E, Steinberg C, Pawar RD, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008; 58: 1107-1115.
96. Thibault DL, Chu AD, Graham KL, et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J. Clin. Invest. 2008; 118: 1417-1426.
97. Pawar RD, Patole PS, Ellwart A, et al. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. Journal of the American Society of Nephrology: JASN 2006; 17: 3365-3373.
98. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL,. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007; 37: 3582-3586.
99. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-671.
100. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L,. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001; 10: 484-490.
101. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F,. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. Arthritis Rheum. 2008; 58: 251-262.
102. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB,. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 2009; 182: 1192-1201.
103. Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 2005; 76: 528-537.
104. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK,. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008; 58: 2481-2487.
105. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 2007; 357: 977-986.
106. Cunninghame Graham DS, Akil M, Vyse TJ,. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology 2007; 46: 927-930.
107. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK,. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007; 8: 492-502.
108. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK,. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008; 58: 2113-2119.
109. Sigurdsson S, Nordmark G, Garnier S, et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 2008; 17: 2868-2876.
110. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. Plos Med. 2006; 3: e491.
111. Fu Q, Chen X, Cui H, et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res. Ther. 2008; 10: R112.
112. Yao Y, Higgs BW, Richman L, White B, Jallal B,. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res. Ther. 2010; 12 (Suppl 1): S6.
113. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 2011; 70: 1905-1913.
114. Jacob CO, McDevitt HO,. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-358.
115. Kontoyiannis D, Kollias G,. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol. 2000; 30: 2038-2047.
116. Yokoyama H, Kreft B, Kelley VR,. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 1995; 47: 122-130.
117. Brennan DC, Yui MA, Wuthrich RP, Kelley VE,. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 1989; 143: 3470-3475.
118. Edwards CK, 3rd, Zhou T, Zhang J, et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J. Immunol. 1996; 157: 1758-1772.
119. Deguchi Y, Kishimoto S,. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin. Exp. Immunol. 1991; 85: 392-395.
120. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. 1997; 24: 303-308.
121. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM,. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002; 360: 646.
122. Shakoor N, Michalska M, Harris CA, Block JA,. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580.
123. Atzeni F, Ardizzone S, Sarzi-Puttini P, et al. Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study. Aliment. Pharmacol. Ther. 2005; 22: 453-461.
124. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003; 48: 1015-1023.
125. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F,. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005; 52: 2192-2201.
126. Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T,. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin. Exp. Rheumatol. 2008; 26: 401-407.
127. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J. Clin. Immunol. 2008; 28: 445-455.
128. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P,. Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 2005; 1051: 559-569.
129. Neale TJ, Ruger BM, Macaulay H, et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am. J. Pathol. 1995; 146: 1444-1454.
130. Aringer M, Graninger WB, Steiner G, Smolen JS,. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum. 2004; 50: 3161-3169.
131. Hayat SJ, Uppal SS,. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod. Rheumatol. 2007; 17: 174-177.
132. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients. Rheumatology 2009; 48: 1451-1454.
133. Esfandiari E, McInnes IB, Lindop G, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 2001; 167: 5338-5347.
134. Favilli F, Anzilotti C, Martinelli L, et al. IL-18 activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 2009; 1173: 301-309.
135. Faust J, Menke J, Kriegsmann J, et al. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum. 2002; 46: 3083-3095.
136. Menke J, Bork T, Kutska B, et al. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int. 2011; 79: 452-463.
137. Bossu P, Neumann D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. U.S.A. 2003; 100: 14181-14186.
138. Wong CK, Ho CY, Li EK, Lam CW,. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593.
139. Wong CK, Ho CY, Li EK, Tam LS, Lam CW,. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2002; 130: 345-351.
140. Amerio P, Frezzolini A, Abeni D, et al. Increased IL-18 in patients with systemic lupus erythematosus: Relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin. Exp. Rheumatol. 2002; 20: 535-538.
141. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F,. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin. Exp. Immunol. 2004; 138: 171-178.
142. Park MC, Park YB, Lee SK,. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin. Rheumatol. 2004; 23: 225-229.
143. Shibatomi K, Ida H, Yamasaki S, et al. A novel role for interleukin-18 in human natural killer cell death: High serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 2001; 44: 884-892.
144. Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M,. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum. 2008; 58: 3205-3215.
145. Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ,. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J. Immunol. 2011; 187: 6143-6156.
146. Nold M, Hauser IA, Hofler S, et al. IL-18BPa:Fc cooperates with immunosuppressive drugs in human whole blood. Biochem. Pharmacol. 2003; 66: 505-510.
147. Hayat SJ, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M,. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin. Rheumatol. 2007; 26: 973-975.